Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELN-128
- Development stage
- Preclinical
- Lead developer
- Elenae Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ELN-128 is a preclinical-stage antisense oligonucleotide (ASO) developed by Elenae Therapeutics. It is designed as a Locked Nucleic Acid (LNA) mixmer that specifically targets and inhibits microRNA-128-3p (miR-128-3p). miR-128 is a key regulator of cardiac regeneration and remodeling; its inhibition is intended to promote cardiac repair and prevent the progression to heart failure following a myocardial infarction (MI). ELN-128 is currently undergoing preclinical evaluation in non-human primate and porcine models for early post-MI remodeling and heart failure prevention. The program is also being expanded to address cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD).
- Other names
- ELN-128ELN128ELN 128
Beyond the preview
Go deeper on ELN-128.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELN-128.